The Trump administration is crafting plans that would allow the temporary sale of certain previously restricted peptides while federal health officials develop new regulations around the controversial products, according to two people familiar with the matter.
The reported approach would rely on a mechanism known as interim enforcement discretion, under which the FDA would temporarily refrain from enforcing restrictions against specific compounded drugs while a formal regulatory review continues. The FDA is weighing whether to allow compounding pharmacies to produce seven peptide treatments for conditions including insomnia, obesity, and wound healing.
The plan has not been finalized, and its status remains reported rather than confirmed. But if implemented, it would represent a significant softening of federal enforcement against unapproved peptide compounds and could reshape access for patients, prescribers, and the compounding industry.
What happened
According to the report, the administration is preparing a pathway that would let state-licensed pharmacies prepare the peptide drugs for patients with valid prescriptions. The Alliance for Pharmacy Compounding, an industry trade group, has been seeking interim enforcement discretion from the FDA.
Under the framework described, pharmacies would operate under enhanced disclosure requirements and adverse event reporting conditions — guardrails intended to provide visibility into how the compounds are used and any problems that arise.
The seven peptide treatments under consideration target conditions including insomnia, obesity, and wound healing. The FDA has not confirmed the plan, and no interim enforcement discretion policy has been announced.
Why it matters
According to the report, peptides have been prescribed through telehealth platforms and compounding pharmacies despite lacking FDA approval as drugs. FDA career scientists have previously said the compounds lack sufficient evidence of safety and effectiveness, according to the report.
A policy of interim enforcement discretion would create a temporary legal pathway for these products — a notable departure from the agency’s traditional position that unapproved drugs should not be marketed. For compounding pharmacies, both 503A traditional pharmacies and 503B outsourcing facilities, it could reduce regulatory risk. For telehealth companies that prescribe peptides, it could expand the range of treatments they can lawfully offer.
For patients, the change could mean easier access to compounds that regulators have previously restricted. That access comes with the caveat that FDA career scientists have cited insufficient safety and effectiveness evidence for these products — a concern that interim enforcement discretion would not resolve, but rather set aside temporarily while formal review proceeds.
State pharmacy boards, which oversee compounding pharmacies, would also be affected, since enforcement discretion at the federal level would change how state-licensed pharmacies operate within their jurisdictions.
What to watch next
- Whether the FDA formally announces an interim enforcement discretion policy, and which specific peptides it covers.
- The conditions attached to any such policy, including disclosure and adverse event reporting requirements for compounding pharmacies.
- How the agency’s career scientists and leadership respond, given prior concerns about safety and effectiveness evidence.
- Whether the seven peptide treatments under consideration are ultimately moved through a formal regulatory review, and what that review concludes.
- Reactions from state pharmacy boards, telehealth prescribers, and industry groups such as the Alliance for Pharmacy Compounding.
For now, the plan remains in the drafting stage. No enforcement policy has changed, and compounded peptides that are currently restricted remain restricted until the FDA acts.
Sources
- DNYUZ — Trump Administration Paving Way for Temporary Sale of Some Unapproved Peptides
- Political Wire — Trump Moves to Allow Sale of Untested Peptides
Industry information only. Not medical or legal advice.
